Please assess the completion status of the following clinical trial:

Trial Title: Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Adult Patients With Severe Gram-Negative Lower Respiratory Tract Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and non-pregnant, non-lactating females, 18 years of age or older~2. Currently intubated and mechanically-ventilated subjects in the ICU~3. Suspicion of lower respiratory tract infection~4. Presence of Gram-negative organism(s) by Gram stain OR by culture of pre-therapy respiratory specimen (eg, endotracheal aspirate \[ETA\], bronchoalveolar lavage \[BAL\], or mini-BAL) OR previous colonization 48 h before screening.~5. Initial empiric antimicrobial meropenem regimen~6. At least two risk factors for multidrug-resistant organisms~7. Provision of written informed consent by the subject or a family member or a close relative or waiver of consent.~Exclusion Criteria:~1. Subjects who have received antibiotic therapy for Gram-negative LRT infection for ≥ 36 hours at the time of randomization~2. Subjects with known or suspected type 1 hypersensitivity to beta-lactam and/or cephalosporin~3. Subjects taking valproic acid for a seizure disorder~4. Subjects who have had a left hemisphere stroke within five days and there is an increased risk of fatal brain oedema~5. Subjects who have cystic fibrosis, human immunodeficiency virus (HIV) infection with CD4 count \<100 cell/mm3 or invasive fungal infection of the lung~6. Neutropenia (ANC \< 103 neutrophils/mm3)~7. Bone marrow transplant.~8. Subjects who have been on mechanical ventilation for \>28 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: MON4STRAT Strategy (Type: EXPERIMENTAL): None
- Group 2: Conventional treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).